Work

Reply to Charra et al.: Global longitudinal assessment of 2019 changes in defined daily doses

Year: 2018

Type: letter

Abstract: The concept of defined daily doses (DDDs) is rooted in the understanding that to assess drug utilization and to develop rational interventions at the patient level, a common framework for comparing varied sources and forms of drug utilization data are necessary (1⇓–3). A primary aim of the WHO Collaborating Centre for Drug Statistics Methodology (WHO-CC-DSM), which maintains DDD values, is to keep DDD values as stable as possible for the purposes of evaluating longitudinal drug utilization data. Because the DDDs for antibiotics have been a matter of debate for many years, the WHO-CC-DSM decided to implement DDD changes for several Anatomical Therapeutic Chemical (ATC) classification codes [ATC/DDD Index; e.g., amoxicillin (J01CA04) and amoxicillin/clavulanic acid (J01CR02)] starting January 1, … [↵][1]1To whom correspondence should be addressed. Email: klein{at}cddep.org. [1]: #xref-corresp-1-1

Source: Proceedings of the National Academy of Sciences

DOI: 10.1073/pnas.1817182115

Authors: Eili Y. Klein, Katie K. Tseng, Simon A. Levin, Herman Goossens, Ramanan Laxminarayan

Institutions: Center for Disease Dynamics, Economics & Policy, Johns Hopkins University, Johns Hopkins Medicine, Princeton University, High Meadows Environmental Institute, University of Antwerp, University of Washington

Language: English

Topic: Pharmaceutical Economics and Policy

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2901608152

Cites: 4

Cited by: 4

Related to: 10